Suppr超能文献

泰国人玻璃体内注射组织型纤溶酶原激活剂及膨胀性气体治疗黄斑下出血的结果

Results of intravitreal tissue plasminogen activator and expansile gas injection for submacular haemorrhage in Thais.

作者信息

Ratanasukon M, Kittantong A

机构信息

Retina Unit, Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University, Songkhla, Hat yai, Thailand.

出版信息

Eye (Lond). 2005 Dec;19(12):1328-32. doi: 10.1038/sj.eye.6701769.

Abstract

PURPOSE

To study the results of intravitreal tissue plasminogen activator (tPA) and expansile gas injection for submacular haemorrhage in Thai patients.

METHODS

The medical records of Thai patients who presented with submacular haemorrhage between January 1998 and December 2002 were reviewed. The inclusion criteria were acute onset of bleeding (<1 month), treatment with intravitreal injection of tPA solution (50-100 mug in 0.1 ml) and expansile gas (0.3-0.4 ml of 100% perfluoropropane or sulphur hexafluoride), and at least 6 months of follow-up. Our main outcome measures were best final postoperative visual acuity and surgical complications.

RESULTS

A total of 19 eyes of 19 patients completed the inclusion criteria with a mean duration of 13.1 days. The causes of haemorrhage were age-related macular degeneration in 15 eyes (78.9%), idiopathic choroidal neovascularization in two eyes (10.5%), and traumatic, and valsalva retinopathy in one eye each (5.2%). After a mean follow-up of 13 months (range 6-39 months), postoperative visual acuity improved two lines or greater in 12 eyes (63.2%), stabilized in six eyes (31.6%) and worsened in one (5.2%). The final visual acuity measured 20/63 or better in 10 eyes (52.6%). The surgical complications were breakthrough vitreous haemorrhage (three eyes) and cataracts (three eyes), and two had retinal detachments.

CONCLUSION

The treatment of submacular haemorrhage with intravitreal injection of tPA and expansile gas improved visual acuity in more than half of the patients. In all, 10 in 19 eyes demonstrated final visual acuity at a functional level.

摘要

目的

研究泰国患者玻璃体内注射组织型纤溶酶原激活剂(tPA)联合膨胀性气体治疗黄斑下出血的效果。

方法

回顾1998年1月至2002年12月期间泰国黄斑下出血患者的病历。纳入标准为急性出血发作(<1个月)、玻璃体内注射tPA溶液(0.1ml含50 - 100μg)和膨胀性气体(0.3 - 0.4ml 100%全氟丙烷或六氟化硫)治疗,且随访至少6个月。我们的主要观察指标是术后最佳最终视力和手术并发症。

结果

19例患者的19只眼符合纳入标准,平均病程为13.1天。出血原因包括年龄相关性黄斑变性15只眼(78.9%)、特发性脉络膜新生血管2只眼(10.5%)、外伤和瓦尔萨尔瓦视网膜病变各1只眼(5.2%)。平均随访13个月(6 - 39个月)后,1级以上(行数)的术后视力提高12只眼(63.2%),稳定6只眼(31.6%),恶化1只眼(5.2%)。最终视力20/63或更好的有10只眼(52.6%)。手术并发症为玻璃体出血突破(3只眼)和白内障(3只眼),2例发生视网膜脱离。

结论

玻璃体内注射tPA联合膨胀性气体治疗黄斑下出血使半数以上患者视力提高。19只眼中共有10只眼最终视力达到功能水平。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验